BRIEF-Eikon Therapeutics Announces First Patient Dosed In Teluride-008, A Registrational Phase 2/3 Trial Of Eik1001 In Non-Small Cell Lung Cancer
EIKN•Eikon Therapeutics announces first patient dosed in Teluride-008
July 27 (Reuters) - Eikon Therapeutics Inc EIKN.O:
- Eikon Therapeutics announces first patient dosed in Teluride-008, a registrational Phase 2/3 trial of Eik1001 in non-small cell lung cancer
Source text: ID:nGNX47P4Lf
Further company coverage: EIKN.O
